Global Attention-Deficit Hyperactivity Disorder (ADHD) Market to Register Strong Growth at CAGR of 6.7% by 2026 | Worldwide Top Key Players – lcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.)

Global Attention-Deficit Hyperactivity Disorder (ADHD) Market by Drug Type (Stimulants, Non- Stimulants), Therapy Type (Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy), End- User (Specialty Clinics, Retail Pharmacies, Hospital Pharmacies, e-Commerce), Demographic Type (Adult (Aged 18 and above), Children), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026

Market Analysis: Global Attention-Deficit Hyperactivity Disorder Market

Global Attention-Deficit Hyperactivity Disorder Market is expected to rise gradually to an estimated value of USD 17.57 billion by 2026, registering a CAGR of 6.7% in the forecast period of 2019-2026 with the annual sales in 2018 accounted for USD 10.46 billion. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of infants.

Market Definition: Global Attention-Deficit Hyperactivity Disorder Market

Attention-deficit hyperactivity disorder is defined as a brain disorder in which the patient is hyperactive, impulsive and lacks attention. The cause of this disorder is not yet known but it is expected that a no. of factors like genes, pre-natal brain injuries, exposure of toxins etc. are responsible for ADHD.

Download PDF Sample report @

Key Market Competitors: Global Attention-Deficit Hyperactivity Disorder Market

Takeda Pharmaceutical Company Limited (Japan), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.), and Curemark, LLC. (U.S.), MonoSol Rx(U.S.), KemPharm, Inc. (U.S.), Neurosigma, Inc. (U.S.), Impax Laboratories, LLC (US), Hisamitsu Pharmaceutical Co.,Inc. (Singapore), Mallinckrodt (UK), UCB S.A. (Belgium), Purdue Pharma L.P. (US), Johnson & Johnson Services, Inc. (US) and Actavis (U.S.) and few among others.

Market Drivers

  • Increase in focus & advancements in medical field to develop innovative products for ADHD.
  • Increase in awareness about mental illness among people.

Global Attention-Deficit Hyperactivity Disorder Market report is a comprehensive study about the market which tells about what is the market status in the forecast period of 2019-2026. This analysis gives an examination of various segments that are relied upon to witness the quickest development amid the estimate forecast frame. Analysis and discussion of important industry trends, market size, market share estimates are mentioned in the report. This Attention-Deficit Hyperactivity Disorder Market study also analyzes the market status, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis.

Market Restraints

  • Strict government & regulatory guidelines, and increase in the cost of the medication may hamper the market.
  • Limited availability of non-stimulants ADHD drugs will restrain the market.

Table of Contents:

  1. Introduction
  2. Market Segmentation
  3. Market Overview
  4. Executive Summary
  5. Premium Insights
  6. Global, By Component
  7. Product Type
  8. Delivery
  9. Industry Type
  10. Geography

10.1. Overview

10.2. North America

10.3. Europe

10.4. Asia-Pacific

10.5. South America

10.6. Middle East & Africa

  1. Company Landscape
  2. Company Profiles
  3. Related Reports

To Continue…….!!! | Get Detailed TOC: @

Segmentation: Global Attention-Deficit Hyperactivity Disorder Market

  • By Drug Type
    • Stimulants
    • Non-stimulants
  • By Therapy Type
    • Behavior Therapy
    • Cognitive Behavioral Therapy
    • Interpersonal Psychotherapy
    • Family Therapy
  • By End-User
    • Specialty Clinics
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacy
  • By Demographic type
    • Adult (Aged 18 and above)
    • Children
  • By Geography
    • North America
      • US
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Thailand
      • Malaysia
      • Indonesia
      • Philippines
      • Rest of Asia Pacific
    • Middle East & Africa
      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East & Africa

Key Developments in the Market:

  • On 20th June 2017, Shire Pharmaceuticals received the US-FDA approval for its product Mydayis, which is Adderall XR (Amphetamine/dextroamphetamine) with the extended delivery. The company has worked on increasing the product life-cycle to generate the revenue. This will help company to grow in the ADHD therapeutic market.
  • On 7th December 2015, Pfizer Inc. has got US-FDA approval for innovative chewable tablets of Methylphenidate under the product name QUILLICHEW ER (extended-release) for patients of 6 and above age group.

Competitive Analysis: Global Attention-Deficit Hyperactivity Disorder Market

Global attention-deficit hyperactivity disorder market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of attention-deficit hyperactivity disorder market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

  • Current and future of global attention-deficit hyperactivity disorder market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)


About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.



Data Bridge Market Research

Tel: +1-888-387-2818



Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *